Yusuke Shimakawa1,2,3, Maud Lemoine1,4, Harr Freeya Njai1, Christian Bottomley2, Gibril Ndow1,5, Robert D Goldin4, Abdoulie Jatta1, Adam Jeng-Barry1, Rita Wegmuller6, Sophie E Moore2,6, Ignatius Baldeh7, Makie Taal7, Umberto D'Alessandro1,2, Hilton Whittle8, Ramou Njie1,5, Mark Thursz4, Maimuna Mendy9. 1. Medical Research Council (MRC) Unit, Banjul, The Gambia. 2. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. 3. Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France. 4. Department of Hepatology, Imperial College London, London, UK. 5. The Gambia Hepatitis Intervention Study, IARC, c/o MRC Unit, Banjul, The Gambia. 6. MRC International Nutrition Group, MRC Keneba, West Kiang, The Gambia. 7. Ministry of Health and Social Welfare, Banjul, The Gambia. 8. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. 9. International Agency for Research on Cancer (IARC), Lyon, France.
Abstract
BACKGROUND: The natural history of chronic HBV infection in sub-Saharan Africa is unknown. Data are required to inform WHO guidelines that are currently based on studies in Europe and Asia. METHODS: Between 1974 and 2008, serosurveys were repeated in two Gambian villages, and an open cohort of treatment-naive chronic HBV carriers was recruited. Participants were followed to estimate the rates of hepatitis B e (HBeAg) and surface antigen (HBsAg) clearance and incidence of hepatocellular carcinoma (HCC). In 2012-2013, a comprehensive liver assessment was conducted to estimate the prevalence of severe liver disease. RESULTS: 405 chronic carriers (95% genotype E), recruited at a median age of 10.8 years, were followed for a median length of 28.4 years. Annually, 7.4% (95% CI 6.3% to 8.8%) cleared HBeAg and 1.0% (0.8% to 1.2%) cleared HBsAg. The incidence of HCC was 55.5/100 000 carrier-years (95% CI 24.9 to 123.5). In the 2012-2013 survey (n=301), 5.5% (95% CI 3.4% to 9.0%) had significant liver fibrosis. HBV genotype A (versus E), chronic aflatoxin B1 exposure and an HBsAg-positive mother, a proxy for mother-to-infant transmission, were risk factors for liver fibrosis. A small proportion (16.0%) of chronic carriers were infected via mother-to-infant transmission; however, this population represented a large proportion (63.0%) of the cases requiring antiviral therapy. CONCLUSIONS: The incidence of HCC among chronic HBV carriers in West Africa was higher than that in Europe but lower than rates in East Asia. High risk of severe liver disease among the few who are infected by their mothers underlines the importance of interrupting perinatal transmission in sub-Saharan Africa. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND: The natural history of chronic HBV infection in sub-Saharan Africa is unknown. Data are required to inform WHO guidelines that are currently based on studies in Europe and Asia. METHODS: Between 1974 and 2008, serosurveys were repeated in two Gambian villages, and an open cohort of treatment-naive chronic HBV carriers was recruited. Participants were followed to estimate the rates of hepatitis B e (HBeAg) and surface antigen (HBsAg) clearance and incidence of hepatocellular carcinoma (HCC). In 2012-2013, a comprehensive liver assessment was conducted to estimate the prevalence of severe liver disease. RESULTS: 405 chronic carriers (95% genotype E), recruited at a median age of 10.8 years, were followed for a median length of 28.4 years. Annually, 7.4% (95% CI 6.3% to 8.8%) cleared HBeAg and 1.0% (0.8% to 1.2%) cleared HBsAg. The incidence of HCC was 55.5/100 000 carrier-years (95% CI 24.9 to 123.5). In the 2012-2013 survey (n=301), 5.5% (95% CI 3.4% to 9.0%) had significant liver fibrosis. HBV genotype A (versus E), chronic aflatoxin B1 exposure and an HBsAg-positive mother, a proxy for mother-to-infant transmission, were risk factors for liver fibrosis. A small proportion (16.0%) of chronic carriers were infected via mother-to-infant transmission; however, this population represented a large proportion (63.0%) of the cases requiring antiviral therapy. CONCLUSIONS: The incidence of HCC among chronic HBV carriers in West Africa was higher than that in Europe but lower than rates in East Asia. High risk of severe liver disease among the few who are infected by their mothers underlines the importance of interrupting perinatal transmission in sub-Saharan Africa. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Antoine Jaquet; Boris Tchounga; Aristophane Tanon; Aklesso Bagny; Didier K Ekouevi; Hamar A Traore; Annie J Sasco; Moussa Maiga; François Dabis Journal: Int J Cancer Date: 2018-04-10 Impact factor: 7.396
Authors: E Seremba; J P Van Geertruyden; R Ssenyonga; C K Opio; J M Kaducu; J B Sempa; R Colebunders; P Ocama Journal: Vaccine Date: 2017-04-20 Impact factor: 3.641
Authors: Anna S Lok; Robert Perrillo; Christina M Lalama; Michael W Fried; Steven H Belle; Marc G Ghany; Mandana Khalili; Robert J Fontana; Richard K Sterling; Norah Terrault; Jordan J Feld; Adrian M Di Bisceglie; Daryl T Y Lau; Mohamed Hassan; Harry L A Janssen Journal: Hepatology Date: 2021-05-21 Impact factor: 17.425